TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01818752

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone 60 mg/m² was taken orally on days 1 to 4 of all cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 60 mg/m² was taken orally on days 1 to 4 of all cycles.
Study: NCT03600350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a growth factor that supports the survival, clonal expansion and differentiation of hematopoietic progenitor cells including dendritic antigen presenting cells.
Study: NCT00541814

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine
Description: Target drug level 50-100 ng/ml or cyclosporine withdrawal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Target drug level 50-100 ng/ml or cyclosporine withdrawal
Study: NCT01924416

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Care (intervention group and comparison group)
Description: Decision aid coupled with immediate QL-PRO results

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care (routine chemotherapy cycles and imaging studies)
Description: Usual care does not receive intervention
Study: NCT02057081

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multifamily Group for mTBI for Couples
Description: MFG-mTBI-C uses a structured problem-solving and skills training approach to provide Veterans and partners with tools and information to improve coping and help couples reconnect through positive behavioral exchanges.
Study: NCT02234271

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Health Application
Description: Mobile Health application for contraception information

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Educator Counseling
Description: Counseling via health educator
Study: NCT01176929

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual treatment and Prevention program
Description: Prevention program of recurrent suicidal acts includes three interventions:~* A series of three telephone calls ( the second week , one month and three months after discharge from hospital )~* A systematic telephone contact with the referring physician~* A telephone helpline for people who made a suicide attempt and referring physicians.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Treatment
Description: Usual Treatment
Study: NCT02253342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WCK-2349
Description: Each subject will receive ten oral doses of 1000 mg WCK 2349 administered twice-daily starting on Day 1
Study: NCT02057081

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Health Education (GHE)
Description: GHE is a 14-session, highly structured educational intervention providing general information on health problems that are common among the general OEF/OIF cohort including sleep and sleep problems, physical activity and exercise, and alcohol and drug use, as well as guidelines for improving health behavior in these areas.
Study: NCT00580671

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MET/CBT
Description: Weekly Individual Counseling Sessions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MET/CBT
Description: Weekly Individual Counseling Sessions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MET/CBT
Description: Weekly Individual Counseling Sessions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CM
Description: Abstinence-based incentives delivered contingent on drug-negative urine test results.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CM
Description: Abstinence-based incentives delivered contingent on drug-negative urine test results.
Study: NCT03317496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab 800 mg in combination with pemetrexed / carboplatin
Description: Avelumab Pemetrexed Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab 800 mg in combination with gemcitabine / cisplatin.
Description: Avelumab Gemcitabine Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab 1200 mg in combination with pemetrexed/carboplatin
Description: Avelumab Pemetrexed Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab 1200 mg in combination with gemcitabine/cisplatin
Description: Avelumab Gemcitabine Cisplatin
Study: NCT04011072

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Far infrared radiation
Description: The treatment group will receive FIR for 40 minutes on the skin above the fistula during each dialysis session for one year.
Study: NCT03507101

Intervention type: OTHER
Intervention: No intervention
Description: No particular intervention or exposure is of particular interest
Study: NCT02587416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcabene 300 mg
Description: 1x300 mg gemcabene tablets orally once daily (QD) for 11 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcabene 900 mg
Description: 3x300 mg Gemcabene tablets orally once daily (QD) for 11 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: 2x40 mg Atorvastatin tablets orally once daily (QD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 2x40 mg Atorvastatin tablets orally once daily (QD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 2x40 mg Atorvastatin tablets orally once daily (QD)
Study: NCT03834168

Intervention type: OTHER
Group type: OTHER
Intervention: standardized Study Diet
Description: Standardized diet consisted with eucaloric meals with 4.5 gm of sodium per day for 5 days.
Study: NCT00316004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7.5% Hypertonic Saline in 6% Dextran-70 (HSD)
Description: 250 ml intravenous bolus administration of 7.5% saline/6% dextran 70 administered as a one-time bolus fluid for initial resuscitation to injured patients with suspected severe traumatic brain injury in the out-of-hospital setting.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7.5% Hypertonic Saline (HS)
Description: 250 ml intravenous bolus administration of 7.5% hypertonic saline administered as a one-time bolus fluid for initial resuscitation to injured patients with suspected severe traumatic brain injury in the out-of-hospital setting.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Normal Saline (NS)
Description: 250 ml intravenous bolus administration of 0.9% saline administered as a one-time bolus fluid for initial resuscitation to injured patients with suspected severe traumatic brain injury in the out-of-hospital setting.
Study: NCT01134042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate/Vilanterol Inhalation Powder
Description: Fluticasone furoate/Vilanterol inhalation powder inhaled orally once daily for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Furoate Inhalation Powder
Description: Fluticasone furoate inhalation powder inhaled orally once daily for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate Inhalation Powder
Description: Fluticasone propionate inhalation powder inhaled orally twice daily for 24 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Inhalation Powder 1
Description: Placebo in novel dry powder inhaler once daily

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Inhalation Powder 2
Description: Placebo in Diskus inhaler twice daily

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Inhalation Powder 2
Description: Placebo in Diskus inhaler twice daily
Study: NCT03434262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given intravenously (IV).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribociclib
Description: Given orally (PO).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribociclib
Description: Given orally (PO).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribociclib
Description: Given orally (PO).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sonidegib
Description: Given PO.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trametinib
Description: Given PO.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given subcutaneously (SQ).
Study: NCT00580671

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BPT
Description: Behavioral parent training involve 14 weekly counseling curriculum to improve parenting skills.
Study: NCT02467426

Intervention type: DRUG
Intervention: Chemotherapy
Description: intraarterial infusion of cisplatin and mithoxantrone
Study: NCT00967980

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral Nerve Block vs. Psoas Compartment Nerve Block
Description: Patients, undergoing hip arthroplasty or hip resurfacing will be randomized to one of two groups: femoral nerve block or psoas compartment nerve block. Patients randomized to femoral nerve block will receive this block prior to surgery. Patients randomized to psoas compartment nerve block will receive this block prior to surgery. Both patients will receive Mepivicaine via catheter prior to surgery and following surgery, Ropivicaine via pain pump.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral Nerve Block vs. Psoas Compartment Nerve Block
Description: Patients, undergoing hip arthroplasty or hip resurfacing will be randomized to one of two groups: femoral nerve block or psoas compartment nerve block. Patients randomized to femoral nerve block will receive this block prior to surgery. Patients randomized to psoas compartment nerve block will receive this block prior to surgery. Both patients will receive Mepivicaine via catheter prior to surgery and following surgery, Ropivicaine via pain pump.
Study: NCT03723967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab with Carboplatin/Paclitaxel
Description: Durvalumab associated with Carboplatin / Paclitaxel as first line treatment in patients with recurrent/metastatic SCCHN not eligible to standard chemotherapy
Study: NCT03248791

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: Phenylephrine variable infusion with a starting rate of 0.75 mcg/Kg/min.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: Norepinephrine variable infusion with a starting rate of 0.1 mcg/Kg/min.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Bupivacaine will be injected in the subarachnoid space with a dose of 10 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Bupivacaine will be injected in the subarachnoid space with a dose of 10 mg
Study: NCT03586570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprocitentan 25mg
Description: Oral tablets in strength of 25 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablets matching aprocitentan tablets
Study: NCT04516954

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent COVID 19 Plasma
Description: A total of 500 ml of convalescent COVID 19 plasma will be transfused intravenously per subject
Study: NCT03113097

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Embryo transfer
Description: Transfer of different qualities of embryos at blastocyst stage

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Embryo transfer
Description: Transfer of different qualities of embryos at blastocyst stage
Study: NCT02972567

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus spp
Description: 9 log10 cfu/capsule. 1 capsule/day for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Maltodextrin
Study: NCT03510741

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Benzoate
Description: Sodium Benzoate will be administered at 1000mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-Acetylcysteine
Description: N-Acetylcysteine 1000 mgs twice daily dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo added to TAU
Study: NCT02471183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selexipag
Description: Tablets for oral administration containing 200 micrograms (mcg) of selexipag to be administered twice a day. The individual dose is to be established during the first 12 weeks of the study. Doses are in the range from 200 micrograms (1 tablet) to 1,600 micrograms (8 tablets).
Study: NCT03510741

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Benzoate Plus N-Acetylcysteine
Description: Sodium Benzoate will be administered at 1000mg daily and NAC 1000 mgs twice daily dose
Study: NCT04007354

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ventilation method
Description: Depending on the group assignment, mechanical ventilation or spontaneous breathing was performed.
Study: NCT03603678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2253651
Description: 100 µg (500 µg/ml \* 200 µl) BAY2253651 intranasally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2253651
Description: 100 µg (500 µg/ml \* 200 µl) BAY2253651 intranasally
Study: NCT03077776

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Biopsy of primary tumour to be performed prior to initiation of neoadjuvant chemotherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy (optional)
Description: \[Optional\] biopsy of primary tumour to be performed after 4 weeks of neoadjuvant chemotherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy (metastatic)
Description: Biopsy of metastatic site to be performed at the time of relapse
Study: NCT03603678

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo dosing
Study: NCT00961909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5095932
Description: cohorts receiving multiple ascending doses, sc once weekly for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5095932
Description: dose titration to target dose, sc once weekly for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: stable dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: metformin
Description: stable dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: stable dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: metformin
Description: stable dose
Study: NCT03946527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanreotide
Description: Participants will receive lanreotide 120 mg deep subcutaneous injection every 4 weeks (±7 days) for 52 weeks, followed by an extension phase in which all patients will continue to receive lanreotide 120 mg injection every 4 weeks (±7 days) if there is no evidence of disease progression.
Study: NCT02019069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal cytarabine-daunorubicin CPX-351
Description: Given IV
Study: NCT04032938

Intervention type: PROCEDURE
Intervention: extracorporeal circulation during cardiac surgery
Description: We will observe the cardiopulmonary bypass status and time of patients undergoing cardiac surgery and extracorporeal circulation due to their medical needs.
Study: NCT00539474

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radio guided occult lesion localisation
Description: ROLL procedure using the Europrobe (Europrobe, Strassbourg, France) WGL using a hook wire

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radio guided occult lesion localisation
Description: ROLL procedure using the Europrobe (Europrobe, Strassbourg, France) WGL using a hook wire
Study: NCT00961909

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: sc once weekly for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: sc once weekly for 4 weeks
Study: NCT03018483

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Variable PSV
Description: Pressure support is to a targeted mean tidal volume of 6 to 8 ml/kg; the maximal inspiratory pressure ≤40 cmH2O; the flow trigger is set at 2 l/min; inspiratory cycling-off at 25% of peak flow; PEEP and FiO2 for oxygen saturation SaO2 ≥92%, with PEEP ≥5 cmH2O.~In patients ventilated with variable PSV, the pressure support variability is as high as possible (up to 100%), while not exceeding the maximal inspiratory pressure determined by the treating physician.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional PSV
Description: Pressure support is to a targeted mean tidal volume of 6 to 8 ml/kg; the maximal inspiratory pressure ≤40 cmH2O; the flow trigger is set at 2 l/min; inspiratory cycling-off at 25% of peak flow; PEEP and FiO2 for oxygen saturation SaO2 ≥92%, with PEEP ≥5 cmH2O. The adjustment of pressure support until extubation follows these rules for both non-variable and variable PSV groups: pressure support is gradually adjusted in decrements (or increments) of 0 to 5 cmH2O. PEEP is decreased in steps of 0 to 5 cmH2O; PEEP and FiO2 are adjusted to achieve a SaO2 ≥92%, with a PEEP ≥5 cmH2O.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Automated PSV
Description: Pressure support is to a targeted mean tidal volume of 6 to 8 ml/kg; the maximal inspiratory pressure ≤40 cmH2O; the flow trigger is set at 2 l/min; inspiratory cycling-off at 25% of peak flow; PEEP and FiO2 for oxygen saturation SaO2 ≥92%, with PEEP ≥5 cmH2O.Smart CareTM as total automated procedure will be used.
Study: NCT01374386

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exergaming
Description: Participants will have access to Exergaming equipment (video games that require physical activity)
Study: NCT03018483

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NAVA
Description: NAVA level is to a targeted mean tidal volume of 6 to 8 ml/kg; the maximal inspiratory pressure ≤40 cmH2O; the Edi level was increased by step of 0,2 cm/h2o/ mcvolt, PEEP and FiO2 for oxygen saturation SaO2 ≥92%, with PEEP ≥5 cmH2O.
Study: NCT01709032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox and deferiprone
Study: NCT00048958

Intervention type: GENETIC
Intervention: cytogenetic analysis
Study: NCT02059746

Intervention type: OTHER
Intervention: Questionnaires sent by mail
Description: The questionnaires necessary for the study are mailed to patients at 3 and 12 months post-partum.

Intervention type: OTHER
Intervention: Questionnaires sent by mail
Description: The questionnaires necessary for the study are mailed to patients at 3 and 12 months post-partum.
Study: NCT03708835

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transitional care model
Description: In this study, the feasibility and impact of a transitional care model from hospital to home for stroke patients and caregivers will be tested.
Study: NCT03979703

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 12 week yoga class
Description: Intervention is a 12 week yoga class with classes twice a week. Each yoga class will last about 1 hour. Furthermore, focus group interviews will be conducted after the first and last yoga class.
Study: NCT01629225

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Candesartan
Description: To investigate the response to candesartan among southwestern Han Chinese with essential hypertrension
Study: NCT04458480

Intervention type: COMBINATION_PRODUCT
Intervention: Fast Inpatient Rehabilitation
Description: Routine inpatient rehabilitation protocol, administered by licensed Physical Therapist, duration period of 1.5h-2h each time, 2 times for weekdays and 1 time for weekends, totally lasting for 1 week, are applied to the exposed group. After the fast inpatient rehabilitation for 1 week, the patients can get discharged if reaching to the rehabilitation goals of symptoms of pain and swell reduced, knee flexion ≥ 90° and knee extension ≥ 0°, quadriceps femurs and hamstrings muscle strength enhanced, recovery to aided standing and walking, and acquiring of rehabilitation training methods.
Study: NCT03011021

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Dose escalation of Liraglutide starts from 0.6 mg up to 1.2 mg per day.
Study: NCT02709902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene/BP gel, 0.3%/2.5%
Description: Gel
Study: NCT03011021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Dose escalation of Liraglutide starts from 0.6 mg up to 1.2 mg per day.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: UCB-Treg
Description: Receive Treg infusion: 1\~5\*10\^6/kg b.w. in 100ml normal saline

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCB-Treg
Description: Receive Treg infusion: 1\~5\*10\^6/kg b.w. in 100ml normal saline
Study: NCT02709902

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EPIDUO® FORTE
Description: Gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Gel
Study: NCT03011021

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Receive insulin following clinician's instruction.
Study: NCT03416777

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Meat-based diet
Description: Diet including 4 servings per week of red meat (1 serving = 150 g), 3 servings per week of processed meat (1 serving = 50 g), and 1 servings per week of poultry (1 serving = 150 g), for a total amount of 900 g per week of meat.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meat-based diet supplemented with alpha-tocopherol (MBD-T)
Description: Dietary intervention like the MBD with supplementation of alpha-tocopherol at a dosage of 100 mg/die. Available evidence suggests that alpha-tocopherol may help prevent colon cancer by decreasing the formation of mutagens arising from the oxidation of faecal lipids, by decreasing oxidative stress in the epithelial cells of the colon and by molecular mechanisms that influence cell death, cell cycle and transcriptional events (Pierre 2013, Bastide 2016, Bastide 2017, Diallo 2016). It is important to note that 200 mg/day of tocopherol was administered to 20,000 women for 10 years without side effects (Lee et al.,2005).